Table 2.
Demographics, clinical features, and medication use in GBA-PD with severe mutations versus GBA-PD with mild mutations
| GBA-PD with mild mutations (n = 27) | GBA-PD with severe mutations (n = 7) | p value | |
|---|---|---|---|
| Women, n (%) | 11 (40.7) | 6 (85.7%) | 0.09 |
| Age of onset, years | 57 (48, 67) | 58 (45, 62) | 0.61 |
| Time to first evaluation, years | 2.5 (1.0, 6.6) | 1.9 (1.1, 3.4) | 0.80 |
| Duration of disease, years | 7.8 (5.0, 12.8) | 11.6 (9.0, 16.9) | 0.06 |
| Duration of clinical follow-up, years | 4.6 (2.3, 7.2) | 9.5 (5.2, 15.0) | 0.02 |
| UPDRS III at last visit | 20 (15, 32) | 26 (8, 30) | 0.65 |
| Levodopa equivalents at last visit, mg | 675 (400, 1,000) | 733 (575, 1,330.5) | 0.69 |
| Mentation consistently >1, n (%) | 8 (29.6) | 1 (14.3) | 0.64 |
| AcheI >6mo, n (%) | 9 (33.3) | 5 (71.4) | 0.10 |
| Hallucinations >1, n (%) | 11 (40.7) | 6 (85.7) | 0.09 |
| Hallucinations >1 for 6 months, n (%) | 7 (25.9) | 2 (28.6) | 1.0 |
| Antipsychotic >6 months, n (%) | 5 (18.5) | 1 (14.3) | 1.0 |
Continuous variables are reported as medians with interquartile ranges. GBA-PD Parkinson disease with heterozygous GBA mutations, UPDRS Unified Parkinson’s Disease Rating Scale